Merrimack Pharmaceuticals Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Merrimack Pharmaceuticals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 23.2% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
We're Not Worried About Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn
Feb 14
Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth
Sep 23Merrimack Pharmaceuticals GAAP EPS of -$0.04
Aug 04Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation
Mar 19We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Grow
May 19Are Insiders Selling Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Stock?
Feb 22Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its Business
Jan 01Merrimack Pharma jumps 42% on bullish timeline for potential Onivyde milestone payment
Dec 02Merrimack Pharmaceuticals reports Q3 results
Nov 05In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Merrimack Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2023 | N/A | -1 | -1 | -2 | N/A |
| 9/30/2023 | N/A | -1 | -1 | -1 | N/A |
| 6/30/2023 | N/A | -2 | -1 | -1 | N/A |
| 3/31/2023 | N/A | -2 | -2 | -2 | N/A |
| 12/31/2022 | N/A | -2 | -1 | -2 | N/A |
| 9/30/2022 | N/A | -2 | -1 | -2 | N/A |
| 6/30/2022 | N/A | -2 | -2 | -2 | N/A |
| 3/31/2022 | N/A | -2 | 0 | 0 | N/A |
| 12/31/2021 | N/A | -2 | 0 | 0 | N/A |
| 9/30/2021 | N/A | -3 | -1 | -2 | N/A |
| 6/30/2021 | N/A | -4 | -1 | -1 | N/A |
| 3/31/2021 | N/A | -4 | -4 | -4 | N/A |
| 12/31/2020 | N/A | -3 | -2 | -5 | N/A |
| 9/30/2020 | N/A | -3 | -3 | -5 | N/A |
| 6/30/2020 | N/A | -2 | -3 | -9 | N/A |
| 3/31/2020 | N/A | -11 | -13 | -19 | N/A |
| 12/31/2019 | N/A | -21 | -28 | -31 | N/A |
| 9/30/2019 | N/A | -33 | -44 | -48 | N/A |
| 6/30/2019 | N/A | -45 | -58 | -58 | N/A |
| 3/31/2019 | N/A | -53 | -62 | -62 | N/A |
| 12/31/2018 | N/A | -61 | -66 | -66 | N/A |
| 9/30/2018 | N/A | -60 | -72 | -71 | N/A |
| 6/30/2018 | N/A | -53 | -85 | -84 | N/A |
| 3/31/2018 | N/A | -64 | -134 | -133 | N/A |
| 12/31/2017 | N/A | -75 | -127 | -126 | N/A |
| 9/30/2017 | N/A | -102 | N/A | -132 | N/A |
| 6/30/2017 | N/A | -123 | N/A | -141 | N/A |
| 3/31/2017 | N/A | -146 | N/A | -127 | N/A |
| 12/31/2016 | N/A | -155 | N/A | -170 | N/A |
| 9/30/2016 | 21 | -163 | N/A | -143 | N/A |
| 6/30/2016 | 38 | -179 | N/A | -150 | N/A |
| 3/31/2016 | 74 | -151 | N/A | -124 | N/A |
| 12/31/2015 | N/A | -152 | N/A | -105 | N/A |
| 9/30/2015 | 102 | -110 | N/A | -134 | N/A |
| 6/30/2015 | 113 | -95 | N/A | -30 | N/A |
| 3/31/2015 | 105 | -90 | N/A | -38 | N/A |
| 12/31/2014 | 103 | -83 | N/A | -35 | N/A |
| 9/30/2014 | 77 | -107 | N/A | -31 | N/A |
| 6/30/2014 | 56 | -118 | N/A | -114 | N/A |
| 3/31/2014 | 46 | -130 | N/A | -105 | N/A |
| 12/31/2013 | 48 | -131 | N/A | -95 | N/A |
| 9/30/2013 | 54 | -123 | N/A | -87 | N/A |
| 6/30/2013 | 59 | -106 | N/A | -85 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if MACK's forecast earnings growth is above the savings rate (2.4%).
Earnings vs Market: Insufficient data to determine if MACK's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if MACK's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if MACK's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if MACK's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MACK's Return on Equity is forecast to be high in 3 years time